Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?
Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?
复制标题
DOI：
10.1080/2162402x.2015.1112942
复制
发表时间：
2016-04
期刊：
影响因子：
7.2
通讯作者：
Marabelle A
中科院分区：
文献类型：
--
作者：
Brunet LR;Hagemann T;Andrew G;Mudan S;Marabelle A
胰腺癌由于其固有的遗传不稳定性、局部免疫抑制微环境和显著的细胞间质改变而对化疗和放疗具有极强的耐药性。因此，迫切需要改进现有的标准治疗方案。旨在利用内源性抗肿瘤免疫的免疫疗法在多种肿瘤类型中显示出希望。在这篇综述中，我们概述了目前在胰腺癌临床试验中测试的新的免疫相关治疗策略。我们认为，免疫治疗策略与目前的治疗方法相结合，可能为这种最致命的疾病带来新的希望。
Pancreatic cancer is extremely resistant to chemo- and radiation-therapies due to its inherent genetic instability, the local immunosuppressive microenvironment and the remarkable desmoplastic stromal changes which characterize this cancer. Therefore, there is an urgent need for improvement on standard current therapeutic options. Immunotherapies aimed at harnessing endogenous antitumor immunity have shown promise in multiple tumor types. In this review, we give an overview of new immune-related therapeutic strategies currently being tested in clinical trials in pancreatic cancer. We propose that immunotherapeutic strategies in combination with current therapies may offer new hopes in this most deadly disease.